Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
| Status: |
History |
| Expected date of issue: |
August 2010 |
| Wave: |
R |
| Process: |
MTA |
| Topic area:
|
NICE project team
| Executive Lead: |
Andrew Dillon
|
| Technical Lead: |
Whitney Miller
|
| Communications manager: |
Tonya Gillis
|
| Project manager: |
Jeremy Powell
|
|
Assessment group:
|
West Midlands Health Technology Assessment Collaboration |
Provisional schedule
| Consultation on draft scope by stakeholders: |
8 April 2009 |
|
| Closing date for invited submissions / evidence submission: |
10 August 2009 |
| 1st appraisal committee meeting: |
04 February 2010 |
| 2nd appraisal committee meeting: |
06 April 2010 |
Consultees and commentators
|
| Consultees |
Commentators (no right to submit or appeal) |
|
Manufacturers/sponsors
- Abbott Laboratories (adalimumab)
- Bristol-Myers Squibb (abatacept)
- Roche Products (rituximab)
- Schering-Plough (infliximab)
- Wyeth Pharmaceuticals (etanercept)
Patient/carer groups
- Arthritis & Musculoskeletal Alliance (ARMA)
- Arthritis Care
- National Rheumatoid Arthritis Society
- South Asian Health Foundation
Professional groups
- British Health Professionals in Rheumatology
- British Society for Rheumatology
- Primary Care Rheumatology Society
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
Others
Department of Health
Welsh Assembly Government
|
General
- Department of Health,� Social Services and Public Safety for Northern Ireland
- NHS Quality Improvement Scotland
Possible comparator manufacturer(s)
- Alliance Pharmaceuticals (penicillamine) (not participating - no CA&U form)
- Almus Pharmaceuticals (sulfasalazine) (not participating - no CA&U form)
- Arrow Generics (azathioprine) (not participating - no CA&U form)
- Astellas (auranofin) (not participating - no CA&U form)
- AstraZeneca UK (chloroquine)
- Focus Pharmaceuticals (azathioprine) (not participating - no CA&U form)
- Generics (UK) (azathioprine, sulfasalazine, penicillamine) (not participating - no CA&U form)
- GlaxoSmithKline (azathioprine)
- IVAX Pharmaceuticals (azathioprine, sulfasalazine) (not participating - no CA&U form)
- Mayne Pharma (methotrexate) (not participating - no CA&U form)
- Medac UK (methotrexate)
- Novartis (ciclosporin)
- Pfizer (methotrexate, sulfasalazine)
- Roche Products (tocilizumab)
- Sandoz (azathioprine) (not participating -no CA&U form)
- Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
- Schering Plough (golimumab)
- Teva UK (azathioprine, sulfasalazine, penicillamine) (declined to participate)
- UCB Pharma (certolizumab pegol)
- Waymade Healthcare (sulfasalazine) (not participating - no CA&U form)
- Wockhardt UK (methotrexate) (not participating - no CA&U form)
Relevant research groups
- Arthritis Research Campaign
Assessment Group
- West Midlands Health Technology Assessment Collaboration
Associated Guideline Groups
- Scottish Intercollegiate Guidelines� Network (SIGN)
Associated Public Health Groups
|
|
Project history
| Date |
Update |
|
18 March 2009
Ã?Â
|
The Technology Appraisal of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF-α inhibitor ended following the publication of the appeal panel decision in November 2008.Ã? The Institute decided that a new appraisal of the above TNF-α inhibitors should be scheduled into the work programme and combined with a review of technology appraisal guidance 126 (rituximab) and 141 (abatacept).
Ã?Â
|
|
Key documents
This page was last updated: 25 August 2010
